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Background: ECCO essential requirements for quality cancer care (ERQCC) are explanations and descriptions of
challenges, organisation and actions that are necessary to give high-quality care to patients who have a speciﬁc
type of cancer. They are written by European experts representing all disciplines involved in cancer care.
ERQCC papers give oncology teams, patients, policymakers and managers an overview of the elements
needed in any healthcare system to provide high quality of care throughout the patient journey. References are
made to clinical guidelines and other resources where appropriate, and the focus is on care in Europe.
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Melanoma: essential requirements for quality care:
• Melanoma, the most-deadly skin cancer, is rising in incidence among fair-skinned people in Europe.
Increasing complexity of care for advanced disease in clinical areas such as staging and new therapies re-
quires attention to a number of challenges and inequalities in a diverse patient group.
• Care for advanced melanoma must only be carried out in, or in collaboration with, specialist melanoma
centres which have both a core multidisciplinary team and an extended team of allied professionals, and
which are subject to quality and audit procedures. Access to such units is far from universal in all European
countries.
• It is essential that, to meet European aspirations for high-quality comprehensive cancer control, healthcare
organisations implement the requirements in this paper, paying particular attention to multidisciplinarity
and patient-centred pathways from diagnosis to treatment and follow-up, to improve survival and quality of
life for patients.
Conclusion: Taken together, the information presented in this paper provides a comprehensive description of the
essential requirements for establishing a high-quality service for melanoma. The ERQCC expert group is aware
that it is not possible to propose a ‘one size ﬁts all’ system for all countries, but urges that access to multi-
disciplinary teams and specialised treatments is guaranteed to all patients with melanoma.
1. Introduction: why we need quality frameworks
There has been a growing emphasis on driving up quality in cancer
organisations, given that there is wide agreement that much care is not
comprehensively accessible, not well coordinated and not based on
current evidence. This is the starting point of a report by the US
Institute of Medicine (IOM) in 2013 (Levit et al., 2013), which is blunt
in describing a ‘crisis in cancer care delivery’, as the growing number of
older people will mean a rising number of cancer patients and numbers
of survivors, while there are pressures on workforces amid rising costs
of care and complexity of treatments. The European Cancer Concord
(ECC), a partnership of patients, advocates and cancer professionals,
has also recognised major disparities in the quality of cancer manage-
ment and in the degree of funding in Europe, launching a European
Cancer Patient’s Bill of Rights, a patient charter that underpins equi-
table access to optimal cancer control, cancer care and research for
Europe’s citizens (Højgaard et al., 2017).
An assessment of the quality of cancer care in Europe was made as
part of the ﬁrst EU Joint Action on Cancer, the European Partnership for
Action Against Cancer (EPAAC, http://www.epaac.eu), which reported
in 2014 that there are important variations in service delivery between
and within countries, with repercussions in quality of care. Factors such
as waiting times and provision of optimal treatment can explain about a
third of the diﬀerences in cancer survival, while cancer plans, for ex-
ample a national cancer plan that promotes clinical guidelines, pro-
fessional training and quality control measures, may be responsible for
a quarter of the survival diﬀerences.
The EU Joint Action on Cancer Control (CANCON), which replaced
EPAAC from 2014, also focused on quality of cancer care and in 2017
published the European Guide on Quality Improvement in Comprehensive
Cancer Control (Albreht et al., 2017). This recognises that many cancer
patients are treated in general hospitals and not in comprehensive
cancer centres (CCCs), and explores a model of ‘comprehensive cancer
care networks’ that could reconcile expertise in existing healthcare
systems given a lack of CCCs. Research also shows that care provided by
multidisciplinary teams (MDTs) results in better clinical and organisa-
tional outcomes for patients (Prades et al., 2015).
Countries have been concentrating expertise for certain tumour
types in such networks and in dedicated centres, or units, such as for
childhood and rare cancers, and most CCCs have teams for the main
cancer types. For common adult tumours, however, at the European
level there has been widespread eﬀort to establish universal, dedicated
units only for breast cancer, following several European declarations
that set a target of the year 2016 for care of all women and men with
breast cancer to be delivered in specialist multidisciplinary centres.
While this target has not been met (Cardoso et al., 2017), the view of
the ERQCC expert group is that the direction of travel is for all tumour
types to adopt the principles of such dedicated care, as exempliﬁed also
by auditing standards emerging for other cancers such as colorectal.
There are disparities in melanoma burden and outcomes across
Europe that stem from highly heterogeneous organisation of national
health systems, and signiﬁcant diﬀerences in designing and im-
plementing national cancer control plans. To provide optimal quality
care, we consider that melanoma patients must have access to the care
pathways, MDTs and innovative or specialised treatments described in
this document, and which are subject to the same approach to quality
assurance, auditing and accreditation of a ‘unit’ that is emerging in
breast cancer and other tumour types.
2. Melanoma: key facts and challenges
2.1. Key facts
2.1.1. Epidemiology
• Melanoma is a malignant tumour that arises from the pigment-
producing melanocytic cells located mostly in the skin, but also in
the mucosae and ocular structures. In cutaneous melanoma, the
main type of melanoma, there are several clinical and pathological
subtypes, of which the most common is superﬁcial spreading mel-
anoma, which comprises about 70% of cases. Other main subtypes
of cutaneous melanoma are nodular, lentigo maligna and acral
lentiginous (including nail bed melanoma); there are also rare var-
iants such as amelanotic and desmoplastic melanoma. Although it
represents less than 5% of all types of skin cancer, melanoma is the
most deadly, accounting for about 75% of skin cancer-related
deaths. Uveal (eye) melanoma (ciliary body, iris or choroid) is the
most common adult primary intraocular malignancy; conjunctival
melanoma is rare. About half of mucosal melanoma begins in the
head and neck region, and most of the remainder in the ano-rectal
region and female genital tract. Cutaneous and ocular melanoma are
very rare in children.
• The incidence of skin melanoma has increased consistently in fair-
skinned people over the past 4 decades (Nikolaou and Stratigos,
2014). In 2012, it was the 7th most frequently diagnosed cancer in
the European Union (EU) and accounted for 3% of all new cancers,
according to the EUROCARE study (Crocetti et al., 2015). Figures
from EUCAN show that in 2012, more than 100,000 new cases were
registered in Europe (82,000 in EU countries), and there were about
22,000 deaths (16,000 EU), and a 5 year prevalence of about
391,000 (323,000 EU) (Ferlay et al., 2012; Bray et al., 2013). In-
cidence is still rising quickly in some countries − by 5% a year in
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the Netherlands, for example.
• There has been a slight increase in melanoma 5-year survival from
82% in 1999–2001 to 85% in the 2000–2007 period most recently
considered by the EUROCARE study, which also reports higher
survival for certain tumour subtypes (e.g. lentigo melanoma), and
that women have a higher survival for all subtypes. A recent paper
looking at the global picture of melanoma shows that the greatest
burden falls on New Zealand, Australia and Europe, and on older
people and men (Karimkhani et al., 2017). Information on survival
by stage has been limited for skin melanoma; a systematic literature
review that included studies from 9 countries in Europe found that
the reported 5 year overall survival varies: 95%–100% (stage I),
65%–92.8% (stage II), 41%–71% (stage III), and 9%–28% (stage IV),
and concluded that there are large variations in stage-speciﬁc
overall and recurrence-free survival by study type and by country
(Svedman et al., 2016). Despite new treatments, advanced mela-
noma still has a poor prognosis.
• In Europe, there are pronounced diﬀerences among countries in
incidence and mortality, although the quality of cancer registration
varies so deﬁnitive ﬁgures are not available. Reported incidence is
highest in Switzerland (25/100,000 per year), Denmark, Norway
and the Netherlands, and lowest in Central Eastern European (CEE)
countries including Albania, Greece and Romania (below 4/100,000
per year). While the highest mortality rate was in Norway, and the
lowest in Greece, CEE countries have the largest share of deaths
(35.5%) of the 4 European regions (Forsea et al., 2012). A paper that
calculated mortality-to-incidence ratio (MIR) for European countries
for melanoma as a proxy for the fatality rate showed it ranges be-
tween 0.09 in Switzerland and 0.44 in Latvia. The regional average
MIR was the highest in CEE at 0.35; the lowest in Western Europe, at
0.13 (Forsea et al., 2014).
• Estimates for incidence of other melanoma types in Europe are:
ocular, 4000 cases a year; mucosal, 1000; acral lentiginous, 5000;
paediatric, 1000.
2.1.2. Risk factors
The main risk factors for skin melanoma are well established and
include fair skin, excessive exposure to ultraviolet radiation (including
the use of tanning beds) (Boniol et al., 2012), a history of sunburn,
having a large number of moles or some atypical moles, and family
history of melanoma. Immunosuppression is a risk factor for the de-
velopment and aggressive evolution of melanoma.
2.1.3. Diagnosis and treatment
• The appearance of melanoma varies with thickness and subtype.
Most lesions appear as irregular pigmented spots that show early the
signs of ABCDE: Asymmetry, irregular Borders, variegated Colour,
Diameter larger than 6mm and Evolution, i.e. the tendency to
change rapidly over weeks or months. Nodular melanoma may lack
these signs and should be considered in any skin lesion that exhibits
EFG: Evolution, Firmness to touch, and Growth. Lesions are usually
asymptomatic but itching and bleeding can occur in melanomas
with deeper thickness. A lesion that just looks diﬀerent from others
− an ‘ugly duckling’ − may also be a melanoma.
• The use of dermoscopy, serial photography and total body photo-
graphy are helpful in detecting melanomas early. Diagnosis must be
conﬁrmed by a pathologist usually following an excisional biopsy of
the entire lesion. The excisional biopsy is also needed to determine
the thickness of the tumour (Breslow thickness), which is the most
important prognostic factor of the primary in cutaneous melanoma.
Breslow thickness, primary tumour ulceration and lymph node in-
volvement are the main prognostic factors required to stage the
tumour for outcome estimation and management decisions. Sentinel
lymph node biopsy (SLNB) is recommended as a diagnostic and
staging procedure for patients with melanomas thicker than 1mm or
with additional risk factors and is the strongest prognostic marker.
Staging follows the recommendations of the American Joint
Committee on Cancer (Gershenwald et al., 2017).
• The standard treatment for primary cutaneous melanoma is com-
plete surgical excision with safety margins dictated by the tumour’s
depth. Complete lymph node dissection (CLND) is performed for
clinical (macroscopic) stage III disease on conﬁrmation of lymph
node invasion by imaging techniques and cytology/histology. Also,
in patients with a tumour positive SLNB, with high tumour burden
in the sentinel nodes, CLND can be considered by a shared patient-
physician decision (Faries et al., 2017).
• Adjuvant therapies for stage III include interferon α 2b, and clinical
trials of (neo)adjuvant treatment with immune- or targeted thera-
pies have been published recently or are underway. Systemic
therapies exist for unresectable metastatic disease− in recent years
a range of new drugs have been introduced, including (combinations
of) immunotherapies and targeted therapies, which have dramati-
cally changed the prognosis of advanced melanoma. Radiotherapy
can be used as an adjuvant treatment in stage III and to treat re-
currences and metastases (such as in the bones or brain) and for
palliation. Radiotherapy for primary skin melanoma should be
considered in lentigo maligna, especially in older patients with ex-
tensive or unresectable disease. Various strategies such as im-
munotherapy and electrochemotherapy apply in selected cases to
the treatment of isolated (sub)cutaneous metastases or tumours.
Treatment of satellites and in-transit metastases have several treat-
ment options including excision, CO2 laser, electrochemotherapy,
isolated limb perfusion and intra-lesional oncolytic virus therapy
(e.g. T-VEC).
2.2. Challenges in melanoma care
2.2.1. Prevention
Given the rising incidence of melanoma in Europe there is a need for
eﬀective, consistent campaigns about risk factors, especially about ex-
cessive exposure to sunlight and the use of tanning beds, as the IARC
has classiﬁed solar radiation, ultraviolet radiation and UV-emitting
tanning devices as carcinogenic (International Agency for Research on
Cancer (IARC), 2018). There are important diﬀerences in public
awareness of melanoma risk across Europe (Forsea et al., 2013); many
people still do not protect themselves or their children well against the
sun and the use of tanning beds has been banned in only a few countries
so far, although more have instituted bans for those under age 18. The
current legal framework in the EU to regulate the use of tanning devices
lacks harmonisation, as it falls within separate industries, is not well-
enforced or adhered to, and the responsibility lies with national gov-
ernments. Whether regulation comes in the form of bans or restrictions,
matching the right interventions to ﬁt at the country level will be key in
determining its success (European Commission et al., 2016; World
Health Organization, 2017).
2.2.2. Detection and diagnosis
• Early diagnosis of melanoma is crucial to favourable outcomes: the
5 year survival rate is estimated at 95% for stage I melanoma,
thinner than 1mm, but drops to 62% for regional lymph node
spread and below 20% for metastasised tumours (Balch et al., 2009).
Yet a high proportion of melanomas are still detected late, at greater
thickness or lymphatic spread. Contributing factors include lack of
awareness and insuﬃcient public education (such as with older men
and hard to see areas of the body), low numbers of dermatologists in
rural or remote areas, lack of training, time and incentives for pri-
mary care physicians in recognising early tumours and surveying
high risk patients, and administrative obstacles in the referral
pathway to melanoma specialists. Guidelines for primary care are
essential as there is widespread under- and overdiagnosis and little
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consistency around Europe in referral and surveillance strategies.
Some melanoma subtypes, such as nodular melanoma, may not
display usual ABCDE clinical alarm signs and grow rapidly, and
represent a large proportion of late detected and fatal melanomas
(Mar et al., 2013).
• A suspicious lesion must be referred to a dermatologist experienced
with melanoma. While dermoscopy helps greatly in early diagnosis
of melanoma, this technique is eﬃcient only when performed by
trained experts, and dermoscopy training and equipment avail-
ability vary in Europe (Forsea et al., 2016).
• Paediatric melanoma can be a diagnostic challenge as melanomas at
this age are very rare, may not meet usual ABCDE criteria and may
also be challenging for pathologists to determine their malignant
potential.
2.2.3. Staging
There are many challenges in the staging of melanoma:
• Inappropriate, incomplete removal of primary melanoma, with er-
rors in Breslow thickness, ulceration and mitoses estimation; initial
wide-excision of the primary tumour that may interfere with the
subsequent SLNB procedure; inadequate detection, resection and
evaluation of (sentinel) lymph nodes (Dandekar et al., 2014)
• Diﬀerent use of diagnostic terms/histopathological criteria by pa-
thologists (Patrawala et al., 2016); incomplete histopathological
reports; and not using the most recent TNM classiﬁcation (Niebling
et al., 2013)
• Insuﬃcient knowledge of and experience in detection and treatment
of satellite or in-transit metastasis
• Locoregional staging and follow-up with ultrasound techniques re-
quires updated scanners and speciﬁc operator expertise, which can
lead to inter-observer variability in the ultrasound diagnosis of
lymph node stations and varying outcomes of ﬁne needle aspirations
(Voit et al., 2011)
• Underuse or overuse of diagnostic modalities, such as PET-CT, based
on local availability or non-adherence to guidelines. The rate of
metastatic cases among the patient population is relatively low.
Extensive use of imaging modalities for staging and follow-up of
early lesions may incur high costs, false-positive ﬁndings, radiation
exposure, and potential contrast media-related toxicity and allergy
(Stodell et al., 2017; Holtkamp et al., 2017).
2.2.4. Treatment
• Melanoma is at the forefront of developments in new cancer
therapies, especially for metastatic disease. The past few years have
seen rapid development of innovative drugs, such as anti-CTLA4 and
anti-PD1 immunotherapies, and targeted therapy with BRAF and
MEK inhibitors, that have dramatically changed the prognosis of
melanoma. These treatments require in-depth understanding of the
biology and immune responses of melanoma by oncologists, der-
matologists and other health professionals; their combinations open
many new possibilities that need exploration and they bring new,
complex adverse eﬀects, the management of which will need stan-
dardisation. Thus, they put signiﬁcant pressure on healthcare sys-
tems to provide the required level of expertise, logistics and funding.
• The cost of these new drugs is also a major factor in their avail-
ability. More than 5000 patients with metastatic melanoma in
Europe had no access to the latest drugs, according to data from a
survey carried out in 2015/16, mostly due to reimbursement issues
(Kandolf Sekulovic et al., 2017).
• Various surgical procedures have developed for advanced mela-
noma during a time when there was no eﬀective adjuvant therapy,
and there is known to be diﬀerences in procedures and a lack of high
quality evidence. With rapid progress in new treatments, long-term
loco-regional control and standardised surgical techniques are now
becoming imperative (Pasquali et al., 2017).
• Surgery can also need specialist approaches for locoregional re-
currences, (multiple) in-transit metastases and lesions on locations
such as the face and where cosmetic issues are important. Plastic
surgeons need appropriate oncology training when they perform
these procedures.
• Metastatic melanoma often spreads to the brain and latest techni-
ques to treat brain metastases may not be available.
• Overall, decision making in advanced melanoma can now be com-
plex concerning whether to carry out procedures such as lymph
node dissection, and entering patients in trials for neo-adjuvant
therapy.
2.2.5. Screening and counselling
There is no deﬁnitive evidence that population-based screening is
eﬃcient in decreasing mortality. However, targeting high-risk groups
may improve cost-eﬀectiveness and the beneﬁt-harm balance of
screening interventions (Wu et al., 2016; Johnson et al., 2017; Hübner
et al., 2017). There is increasing knowledge about genetic susceptibility
of melanoma, and genetic counselling is likely to become increasingly
important, not only for melanoma but also for other cancers induced by
the same genetic alterations (Potrony et al., 2015). Routine genetic
testing is not yet recommended, and is hampered by cost and the short
supply of genetic experts, although initial counselling can be carried out
by well-informed dermatologists.
2.2.6. Inequalities
People with melanoma in Central and Eastern Europe have up to
40% lower 5 year survival rates than those in North and West Europe.
This is likely to be a result of disparities across the cancer control
spectrum, including access to the latest therapies and to clinical studies
for new treatments. A survey found that patients at 34 oncology centres
in 29 European countries may not have access to innovative drugs such
as BRAF and MEK inhibitors. In Western Europe, 70% of patients were
treated with innovative medicines; however, in 41% of Eastern and
Southeastern Europe less than 10% of patients had access to these same
medicines (Kandolf Sekulovic et al., 2017).
2.2.7. Special groups and rare cancers
Young people –While paediatric cancer units are available in many
countries, units with expertise and appropriate facilities to meet the
needs of adolescents and young adults are fewer, but are also required,
given that melanoma is among the more common cancers in these age
groups. For example, melanoma is the third most common cancer in
ages 15–39 in the USA (Weir et al., 2011) and the second most common
in those aged 25–49 in the UK (where more than 900 adults under the
age of 35 are now diagnosed each year with melanoma) (National
Institute for Health and Care Excellence (NICE), 2015). Education for
awareness of melanoma and fertility preservation are other challenges.
Older people – Signiﬁcant numbers of patients diagnosed with
melanoma are above the age of 65 and the number is expected to in-
crease owing to ageing of the population. Older patients with mela-
noma are heterogeneous, with diﬀerences in the number and severity of
comorbidities, functional status and patient preferences. They are more
often diagnosed with aggressive prognostic features such as thicker
(Breslow) melanomas, higher mitotic rate and more ulceration than
younger patients (Kruijﬀ et al., 2012; Balch et al., 2013). Older patients
also receive less aggressive treatment concerning SLNB, lymph node
dissection and systemic treatment. The mortality rate is higher in older
patients, even within subgroups of Breslow thickness. Frailty is nega-
tively associated with disease free survival and rate of surgical com-
plications (Lange et al., 2011). Age related diﬀerences in pathways to
diagnosis may be associated with later diagnosis or inaccurate staging,
which may lead to worse prognosis.
Rare cancers− Several melanoma types are rare and are included
in projects that are increasing epidemiological and policy knowledge in
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Europe. See RARECARE (www.rarecare.eu), Rare Cancers Europe
(www.rarecancerseurope.org) and PaedCan (http://paedcan.ern-net.
eu), a European Reference Network for paediatric oncology.
2.2.8. Survivorship and surveillance
• Given the rapid expansion of novel treatment options for metastatic
melanoma with long-term results, such as immunotherapies, there is
likely to be an increasing need for support for long-term side-eﬀects,
and management of melanoma as a chronic disease.
• Long-term follow-up is required for melanoma patients to detect
early recurrences, new secondary melanomas, and other related
cancers. But a challenge is avoiding unnecessary and costly follow-
up schemes, as there is no deﬁnite consensus on optimal methods
and schedules of follow-up.
2.2.9. Cancer registration and data availability
Cancer registration practice, coverage and quality are highly un-
equal across Europe. Moreover, melanoma especially in early stages,
may escape cancer registration as it is diagnosed outside the oncolo-
gical network by facilities with diﬀerent reporting policies (Forsea,
2016). Consequently, basic epidemiological data on incidence, mor-
tality and survival are not uniformly available for all countries. Also,
only a minority of cancer registries can provide suﬃcient data for the
calculation of parameters necessary for the assessment of outcomes and
quality of care (Siesling et al., 2015).
3. Organisation of care
Essential requirements for the organisation of melanoma care are:
• Cancer care pathways that cover the entire patient journey
• Treatment in centres appropriate to the stage and complexity of the
disease
• Timeliness of care
• Multidisciplinary team (MDT) working including core and extended
groups of professionals, in dedicated melanoma centres or units
• Patient-centred approach; patient information and involvement in
decisions
• Audit and quality assurance of outcomes and care processes
• Education of health professionals; policies to enrol patients in clin-
ical trials and capacity to conduct research
• A high-quality cancer registration system that shares data among
centres and countries.
These topics are outlined in the following sections, with reference to
national and European resources and clinical practice guidelines, where
appropriate.
3.1. Care pathways and timelines
• Care for melanoma patients must be organised in pathways that
cover the patient’s journey from their point of view rather than that
of the healthcare system, and pathways must correspond to current
national and European evidence-based clinical practice guidelines
on diagnosis, treatment and follow-up. The European Pathway
Association deﬁnes a care pathway as “a complex intervention for
the mutual decision making and organisation of care processes for a
well-deﬁned group of patients during a well-deﬁned period”. This
broad deﬁnition covers terms such as clinical, critical, integrated,
patient pathways that are also often used. See http://e-p-a.org/care-
pathways and also the WHO framework on integrated people-
centred health services, http://www.who.int/servicedeliverysafety/
areas/people-centred-care.
• An example of a melanoma care pathway is from the National
Institute for Health and Care Excellence (NICE) (National Institute
for Health and Care Excellence (NICE), 2018), which organises its
pathway for someone suspected or diagnosed with cutaneous mel-
anoma into a ﬂowchart for assessment, management and follow-up,
and which is designed to be used alongside a guideline that covers
how healthcare services for people with skin cancer should be or-
ganised in England and Wales. NICE also has accredited guidelines
for uveal melanoma (Nathan et al., 2015).
• GPs and other referrers need timely access to expert assessment of a
suspicious lesion. The maximum time for an appointment with a
specialist for suspected adult cancer in England and Wales is 2
weeks, for example; other Western European countries have shorter
targets.
• Reasonable times to report a diagnosis of melanoma and the op-
portunity to start treatment are crucial to timely treatment and to
the wellbeing of patients. Patients with suspected melanoma must
have a diagnostic excision within 1 week and be referred to be
staged within 3 weeks. However, for early stage patients who have
had a radical diagnostic excision, the time taken for a sentinel node
procedure is not relevant to prognosis (Nelson et al., 2017; Oude
Ophuis et al., 2016).
• After a diagnosis, it must be clear to the patient which professional
is responsible for each step in the treatment pathway and who is
following the patient during the journey (usually called a case
manager or patient navigator) (European Partnership for Action
Against Cancer (EPAAC), 2018). In some countries, case managers
during the main stages of treatment are cancer nurses.
• Follow-up and survivorship must also be part of the care pathway.
As most melanomas in Europe are diagnosed at early stages with
good survival, long-term consequences are not usual, but compli-
cations of diagnostic or therapeutic measures may occur and must
be addressed with continuity and appropriate support.
• For paediatric melanoma, the ERQCC expert group recommends
collaboration with adult melanoma MDTs, and that second opinions
on diagnosis and treatment strategy must be sought.
3.2. Melanoma units/centres
• The nature of melanoma lends itself to a two-tier system of care.
Early stage lesions can be managed by a local dermatology unit that
does not have the MDT needed in a melanoma centre that treats all
cases. It is essential that all advanced cases are seen in, or in col-
laboration with, a specialist melanoma centre; professionals at a
centre can also be part of an extended MDT covering other institutes
and networks.
• An example of a two-tier model is in England and Wales, where
NICE has recommended the establishment of two types of MDT – the
local hospital skin cancer MDT, which could be in a general hospital
and deals with routine early stage cases; and a specialist skin cancer
MDT, likely to be in a cancer centre, which has expertise in ad-
vanced cases and which runs clinical trials (National Institute for
Health and Clinical Excellence (NICE), 2006).
• It is essential that the specialist melanoma centre has signiﬁcant
expertise from a suﬃcient annual number of cases and that the core
MDT has members with melanoma as their only, or one of their
primary, interest(s). On the basis of existing evidence, the ERQCC
expert group recommends that for an institution to be considered as
a melanoma centre for advanced cases it should treat suﬃcient
melanoma patients a year, although a threshold will depend on the
structure of melanoma networks in a region or country and the
distribution of expertise. Such centres must have the infrastructure
and expertise to treat patients with advanced locoregional disease,
such as in-transit metastases and/or lymph node metastases in the
head/neck, axillary, groin or popliteal region; and those with un-
resectable stage IIIC and IV disease. Optional modalities include
electrochemotherapy, CO2 laser therapy, intralesional oncolytic
virus therapy and isolated limb perfusion or infusion.
M.W. Wouters et al. Critical Reviews in Oncology / Hematology 122 (2018) 164–178
168
• For example, in the Netherlands, organisations involved in treating
advanced melanoma must have a minimum case volume of 20 new
patients a year for unresectable IIIC and IV metastatic melanoma,
based on safety reports from clinical trials; (SONCOS (Dutch
Federation of Oncological Societies), 2017) for inguinal, iliac/ob-
turator groin dissections and for isolated limb perfusions a minimum
volume of 10 procedures a year is mandatory. In Germany, certiﬁ-
cation for skin cancer units as an organ cancer centre requires at
least 40 new melanoma cases a year (German Cancer Society (DKG),
2016).
3.3. The MDT − advanced melanoma
Treatment strategies for all advanced melanoma patients must be
decided on, planned and delivered as a result of consensus among a
core MDT that comprises the most appropriate members for the parti-
cular diagnosis and stage of cancer, patient characteristics and pre-
ferences, and with input from the extended community of professionals.
The heart of this decision-making process is normally a weekly or more
frequent MDT meeting where all cases are discussed with the objective
of balancing the recommendations of clinical guidelines with the needs
of the individual melanoma patient.
To properly treat melanoma, it is essential that the core MDT
comprises health professionals from the following disciplines:
• Dermatology
• Pathology
• Radiology
• Nuclear medicine
• Surgery/surgical oncology
• Medical oncology
• Radiation oncology
• Interventional radiology
• Ophthalmology (for uveal melanoma)
• Nursing.
This core MDT meets to discuss:
• All advanced cases after diagnosis and staging to decide on optimal
treatment
• Patients with advanced disease to decide on further treatment and
follow-up
• Patients with a recurrence during follow-up, or where changes to
treatment programmes are indicated and have multidisciplinary
relevance and/or planned deviations from clinical practice guide-
lines.
Healthcare professionals from the following disciplines must also be
available whenever their expertise is required (the ‘extended’ MDT):
• Geriatric oncology
• Oncology pharmacy
• Psycho-oncology
• Paediatric oncology
• Palliative care
• Rehabilitation and survivorship.
There is also an increasing understanding of the genetic predis-
position to melanoma and to treatment response so it may be necessary
soon to add a clinical geneticist to the extended MDT to discuss options
for genetic testing and its results with patients and their families.
3.4. Disciplines in the core MDT
3.4.1. Dermatology
Within the melanoma care pathway, the role of dermatologists
includes:
• Early diagnosis of cutaneous melanoma – primary tumours and re-
currences
• Management of intra-cutaneous neoplastic diseases (primary or
metastatic)
• Dermatological follow-up
• Part of the core MDT managing advanced melanoma.
Dermatologists are likely to work in either a general hospital or
local skin clinic, responsible for diagnosis, staging and excision of early
stage cutaneous melanoma, or in a specialist melanoma centre as a
dermato-oncologist, participating in the MDT on all stages of mela-
noma, but particularly advanced stages.
Essential requirements
• Dermatologists at local skin clinics/hospitals must be responsible for
early diagnosis of cutaneous melanoma, and must have dermoscopy
equipment and training. They must perform the correct diagnostic
biopsy, participate in staging the disease with the local MDT ac-
cording to the latest clinical practice guidelines, and refer advanced
stages to a specialist melanoma centre (Garbe et al., 2016).
• Dermatologists must be able to perform local treatments for cuta-
neous neoplastic disease (basic surgery with appropriate margins,
topical and intralesional treatments, electrochemotherapy where
available).
• Dermatologists at local skin clinics/hospitals must carry out der-
matological follow-up of melanoma patients, and must have the
equipment and training for total body photography and sequential
digital dermoscopy.
• Dermatologists at melanoma centres must identify and screen pa-
tients at high risk of primary and recurrent melanoma and must
counsel patients and relatives about primary and secondary pre-
vention.
• Dermatologists working in specialist melanoma centres must have
major interest and expertise in melanoma and must know state of
the art clinical practice guidelines for the management of advanced
stages, and must participate in the core MDT according to their
expertise.
3.4.2. Pathology
Pathologists play a vital role in the MDT in timely diagnosis, sta-
ging, prognostic/predictive assessment and clinical decision making for
each patient.
Essential requirements
• Pathologists must be aware of the type of tissue specimens and
biopsies performed on melanocytic lesions and have access to all
clinical records, including patient history, clinical diagnosis and any
prior or ongoing treatment.
• Pathologists must establish a correct diagnosis according to the
speciﬁc tumour entities listed in the WHO classiﬁcation and must
supply a pathology report with a list of items for pathological sta-
ging and reﬁnement of prognostic models according to current
guidelines (synoptic check-lists or structured reports are preferred)
(Gershenwald et al., 2017; Scolyer et al., 2013).
• SLNBs must be handled by the same team of pathologists involved in
the reporting of primary melanomas. If this is not possible, there
must be coordination among pathology teams to ensure discussion
of challenging cases. National or, preferably, international protocols
such as that used by the European Organisation for Research and
Treatment of Cancer (EORTC)/European Association of Nuclear
medicine (EANM) for SLNB must be applied (Chakera et al., 2009).
• Second opinion must be provided for all patients with complex
melanocytic skin lesions of uncertain or ambiguous
M.W. Wouters et al. Critical Reviews in Oncology / Hematology 122 (2018) 164–178
169
histopathological diagnosis, including lesions labelled as ‘melano-
cytic tumour of uncertain malignant potential’ (MELTUMP). Access
to the genetic information provided by molecular techniques such as
FISH or aCGH may be helpful for diagnosis and/or assessing prog-
nosis in such challenging cases.
• Second opinion is also mandatory in patients younger than 19 years
old.
• Access to an accredited laboratory for molecular testing must be
guaranteed, not necessarily on site. BRAF mutation testing must be
carried out for unresectable stage III or IV melanoma; it is highly
recommended for high-risk stage IIC and III disease; NRAS and c-kit
testing is recommended for BRAF wild-type in both cases.
3.4.3. Radiology
Diagnostic imaging plays little role in the initial diagnosis of mel-
anoma, although high-resolution sonography is being studied to replace
excision biopsies of cutaneous tumours (Botar-Jid et al., 2016). Imaging
plays a major role in staging and follow-up of melanoma and in post-
treatment assessment of metastatic melanoma. The role of the radi-
ologist is to help assess tumour disease extent, formulate prognosis,
assess treatment response, and detect tumour recurrence.
Essential requirements
• Radiologists must know the peculiar pattern of lymphatic spread of
melanoma (satellitosis, in-transit metastasis, lymph-node metas-
tasis) and of the modality of haematogenous diﬀusion (including
uncommon sites of spread).
• When performing/interpreting imaging studies, radiologists must be
aware of patient history; knowledge is mandatory of the primary
melanoma site, of SLNB localisation (if investigated), of the SLNB
result, of any prior or concurrent site of metastatic involvement, and
of any previous or ongoing treatment.
• Radiologists must have interaction with the patient – as many su-
perﬁcial tumour localisations are self-palpated, any minimal
symptom or ﬁnding must be considered.
• Radiologists must have latest equipment. This includes dermatology
transducers ( > 15MHz) and colour-Doppler mode for ultrasound,
multidetector scanners (≥16 detector rows) for CT, high magnetic
ﬁeld scanners (≥1.5 T), liver-speciﬁc contrast media, and diﬀusion-
weighted imaging mode for magnetic resonance (MR), workstations
for CT and MR images processing (Catalano et al., 2010). Systems
appropriate to lower the radiation dose must be employed, parti-
cularly for young patients.
• High-resolution ultrasound with Doppler assessment is mandatory
to detect locoregional metastasis. Two-phase liver acquisition (ar-
terial phase and portal phase) CT is necessary to improve both the
sensitivity and speciﬁcity in assessing liver lesions. Chest scans must
include the neck base while pelvic scans must encompass the in-
guinocrural region. MR imaging, and particularly brain MR, must be
performed in case of indeterminate or discrepant CT ﬁndings, or
when radiation therapy is planned (Sofue et al., 2012).
• Radiologists must have expertise in performing ultrasound or CT-
guided percutaneous procedures, including ﬁne needle cytology,
placement of presurgical guidewires, and aspiration of lymphoceles.
• Radiologists assessing melanoma response to treatment must be
made aware of ongoing therapy (immunotherapy, targeted therapy,
isolated limb perfusion, chemoperfusion, electrochemotherapy,
etc.). They must be familiar with peculiar phenomena related to
innovative therapy (pseudoprogression etc.) as well as with the
main related complications. When evaluating the results of che-
motherapy radiologists should use the RECIST 1.1 system but for
immunotherapy, immune-related response criteria should be
adopted (Nishino et al., 2014).
3.4.4. Nuclear medicine
Current nuclear medicine techniques in melanoma are 18F FDG
PET/CT, SLNB with radiotracers, and SPECT or SPECT/CT.
There is evidence of the eﬃcacy of 18F FDG PET/CT in selected
clinical indications (Boellaard et al., 2015), and appropriate use criteria
(AUC) have been published (Jadvar et al., 2017). Clinical situations
where 18F FDG PET/CT presents high eﬃcacy and has an impact on
management are:
• Initial staging of high-risk or advanced disease patients (Jiménez-
Requena et al., 2010). Based on the fact that 18F FDG PET/CT pro-
vides accurate initial staging, it has a prognostic value and is key in
management and treatment planning decisions in these patients
• Treatment response evaluation. 18F FDG PET/CT has a strong role in
determining the eﬃcacy of treatment. The AUC score was appro-
priate (score 9 of 9)
• Detection of recurrent disease: 18F FDG PET/CT has a strong role in
determining whether if disease has recurred after completion of
therapy. The AUC score was appropriate (score 7 of 9). Early de-
tection of relapse is key for management decisions
• Guiding biopsies with the information supplied by 18F FDG PET/CT,
improving the probability of a successful extraction of diagnostic
tissue.
SLNB with radiotracers is included in the standard of care;53 SPECT/
CT improves the eﬃcacy of SLNB (Mucientes Rasilla et al., 2009).
The role of the nuclear medicine physician is to oversee all aspects
of 18F FDG PET/CT and SLNB for patients who require these proce-
dures, including indications, multidisciplinary algorithms and man-
agement protocols.
Essential requirements
• 18F-FDG PET/CT, SLNB with radiotracers, SPECT/CT and radio-
nuclide therapy must be available and must be managed by nuclear
medicine physicians with the appropriate expertise.
• Nuclear medicine must be able to perform daily veriﬁcation proto-
cols and to react accordingly. Quality-assurance protocols must be in
place. An option for ensuring the high quality of PET/CT scanners is
provided by the European Association of Nuclear Medicine (EANM)
through EARL accreditation.
3.4.5. Surgery
Surgery is the mainstay of the treatment of melanoma, especially in
primary disease, although surgeons are involved in all stages.51 All non-
metastatic adult-type primary melanomas are removed (resected) when
possible as part of frontline treatment; surgery alone can cure more
than 80% of melanoma patients (based on incidence/mortality ﬁgures
before the advent of new therapies).
The role of surgery in advanced melanoma is changing due to the
introduction of immuno- and targeted therapies (van Zeijl et al., 2017).
For oligometastatic disease, surgery with or without adjuvant systemic
therapy can still be the treatment of choice (Lasithiotakis and Zoras,
2017); for locoregional unresectable disease (stage IIIC), surgery can be
performed after downstaging with (combination) immunotherapy or
BRAF and/or MEK inhibitors. For most patients with unresectable stage
IIIC or IV disease, systemic therapy is the ﬁrst line of treatment (Amann
et al., 2017; Franklin et al., 2017).
Surgeons also have a role in resection of residual disease or solitary
sites of disease progression.
Essential requirements
• After diagnosis of a primary non-metastatic melanoma, a ther-
apeutic (re-)excision must be performed by a (dermato)surgeon in-
formed about the excisional margins that have to be kept: 0.5 cm for
melanoma in situ, 1–2 cm for melanoma with a Breslow
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thickness<=2mm and 2 cm for Breslow>2mm.
• For therapeutic re-excisions and surgical staging procedures, there
must be at least two surgeons with expertise in performing sentinel
node procedures in locations speciﬁc to melanoma.
• Melanoma surgeons must have knowledge of and experience with
the peculiar pattern of lymphatic spread of melanoma (satellitosis,
in-transit metastasis, lymph node metastasis) and of the modalities
available to treat these disease entities (CO2 laser, electro-
chemotherapy, intralesional oncolytic virus therapy (e.g. T-VEC)
and isolated limb perfusion or infusion).
• Surgical treatment of patients with cervical, axillary, (ilio)inguinal
or popliteal lymph node disease must be performed at a melanoma
centre, unless arrangements have been made between a melanoma
unit and the specialist centre based on the expertise of the surgeons
in the unit. At least 10 (ilio)inguinal and/or popliteal lymph node
dissections must be performed annually at the unit/centre.
• Advanced surgical treatments for locoregional disease/recurrences
and oligometastatic disease must be available at a melanoma centre.
If isolated limb perfusions are performed at least 10 must be per-
formed annually.
• Specialist surgeons, such as head and neck, plastic, gynaecological
and rectal surgeons, must be available at the centre to operate on
mucosal melanoma sites.
3.4.6. Medical oncology
Systemic treatment should be considered not only for metastatic
disease, but also for any non-operable local disease, as well as in the
adjuvant setting. In a number of metastatic patients, long-term beneﬁt
must now be the main therapeutic objective given the availability of
checkpoint blocking monoclonal antibodies targeting CTLA-4 and PD-1,
targeted therapies acting on the MAPK pathway, and oncolytic viruses
for intralesional therapy. Checkpoint blockade and targeted therapies
are also becoming important in the adjuvant setting. Side-eﬀect man-
agement is becoming a major concern with new therapies, especially
immunotherapies. An up-to-date summary of treatment strategies is
provided by international guidelines such as the ESMO Clinical Practice
Guidelines on melanoma (Dummer et al., 2015).
The role of the medical oncologist is to coordinate the patient
itinerary between dermatology, surgery, radiotherapy and medical
oncology; deliver appropriate therapeutic agents at the appropriate
stage of disease; assess tumour response and subsequent therapeutic
strategies to manage side-eﬀects and melanoma-related symptoms, pain
in particular; manage palliative care with adequate supportive care;
and plan clinical and imaging follow-up for patients rendered disease
free.
Essential requirements
• Medical oncologists must coordinate the patient’s itinerary between
dermatology, surgery, radiotherapy and medical oncology.
• Medical oncologists must ensure proper systemic treatment deci-
sions are made in the MDT in the loco-regional, adjuvant and me-
tastatic settings for targeted therapies and immunotherapies, and in
some cases chemotherapy.
• Tumour response assessment and subsequent therapeutic strategies
must be determined by the medical oncologist in collaboration with
other MDT members.
• Speciﬁc requirements must be carried out, such as cardiac workup
(US and ECG) for MEK inhibitors, and rapid treatment of immune-
related adverse events (irAE) according to algorithms. Medical on-
cologists must be involved with training the extended clinical team
and educating patients in early detection and treatment of irAE.
• Medical oncologists must be trained to detect and treat pain and
other metastatic symptoms according to international guidelines
and must collaborate with palliative care specialists.
• In patients rendered disease free, medical oncologists must
implement a surveillance algorithm, including imaging modalities
depending on the disease stage and relapse risk.
3.4.7. Radiation oncology
Radiotherapy is used to treat melanoma with either curative or
palliative intent, for skin, uveal, conjunctival, mucosal (nasal cavity/
paranasal sinus sinonasal, anogenital) melanoma, and also metastases.
As described in the NCCN (Coit et al., 2016) and ESMO guidelines
(Dummer et al., 2015), radiotherapy should also be considered for local
control.
Radiotherapy can be considered for inadequate resection margins of
lentigo maligna melanoma, or postoperative in regional lymph node
dissections (Henderson et al., 2015), and for positive margins of mel-
anoma metastases when surgery is not adequate. Radiotherapy also has
an important role in the treatment of melanoma brain metastases, by
stereotactic or whole brain radiation. For uveal melanoma, radio-
therapy (proton therapy and ocular brachytherapy) is the best con-
servative treatment giving excellent local control rates (Dendale et al.,
2006; American Brachytherapy Society, 2014). For conjunctival and
mucosal melanomas, adjuvant irradiation is part of the therapeutic
strategy that increases local control rates.
Radiotherapy is a palliative treatment of many symptoms in mela-
noma patients.
It has been reported that the combination of radiotherapy and anti-
PD-1 immunotherapy is well tolerated and leads to a signiﬁcant higher
tumour response rate within and outside the irradiated ﬁeld (abscopal
eﬀect) on patients with metastatic melanoma (Aboudaram et al., 2017).
The role of the radiation oncologist is to determine and prescribe
the most suitable dose of radiation to deliver in a particular case, and
the method and technique by which this will be achieved.
Essential requirements
• Access to radiotherapy must be provided in the melanoma centre or
through a formal collaborative agreement.
• Radiation oncologists participating in melanoma MDTs must have a
special interest and expertise in the biology and treatment of mel-
anoma and have knowledge of the eﬃcacy of radiotherapy in mel-
anoma.
• Access to radiotherapy equipment must be provided depending on
the type of melanoma: 3D conformal RT, IMRT, orthovoltage
radiotherapy, proton therapy, brachytherapy by iodine or ruthe-
nium plaque, stereotactic radiotherapy.
• The radiotherapy centre must have agreed protocols for radio-
therapy and concurrent chemoradiotherapy.
• Radiation oncologists must know the current use of adjuvant
therapy in melanoma and must know about interactions between
systemic therapy and radiotherapy.
• Radiation oncologists must know the indications and contra-in-
dications for adjuvant and deﬁnitive radiotherapy in melanoma, and
inform patients about acute and late side-eﬀects, and interventions
to prevent them from happening or worsening.
• Radiation oncologists must be responsible for follow-up and man-
agement of early and late toxicities.
• Radiation oncologists, radiotherapists and medical physicists must
have expertise in ocular radiotherapy or must refer patients to an
ocular radiation oncologist.
3.4.8. Interventional radiology
Interventional radiology plays an important role in the diagnosis of
advanced melanoma by performing targeted biopsy of melanoma me-
tastases or of unclear lesions, and for treatment of metastases in se-
lected patients. Indeed, image-guided percutaneous core needle biopsy
is crucial in the delivery of a safe and eﬃcient melanoma service. The
role of the interventional radiologist is to:
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• Perform image-guided percutaneous core needle biopsy of unclear
hepatic, pulmonary or bone lesions.
• Provide expertise and support for combined therapies in patients
with metastatic disease with transarterial chemotherapies drug
eluted beads (Venturini et al., 2012), chemoembolisation
(Huppert et al., 2010), chemoperfusion, chemosaturation
or radioembolisation (for the latter with the nuclear medicine
physician) (Eschelman et al., 2013), or ablative therapies for
liver and lung metastases (Shashank et al., 2014; de Baère et al.,
2015).
• Perform appropriate minimally-invasive therapies according to the
MDT’s decision.
Essential requirements
• Biopsies must be performed in melanoma centres by an experienced
interventional radiologist.
• Interventional radiologists performing image-guided biopsies for an
unclear lesion must have training and experience, have access to
appropriate imaging equipment and must implement the WHO
Surgical Safety Checklist.
• Interventional radiologists must work with the MDT to plan the
biopsy in patients who are surgical candidates to avoid the risk of
tumour cell seeding, which may signiﬁcantly hamper surgical re-
section.
• Interventional radiologists must discuss the role and propose use of
local ablative techniques for treating liver, lung or bone metastases
not amenable to, or combined with, surgery.
3.4.9. Ophthalmology
Specialist ophthalmologists carry out diagnosis and treatment
planning of uveal (eye) melanoma. In uveal oncology centres with a
dedicated MDT the risk of misdiagnosis has dropped signiﬁcantly and
such MDTs are essential to a fully functional specialist melanoma centre
or network and to coordinate care pathways at regional and national
levels.
Essential requirements
• Uveal melanoma patients must be served by a MDT consisting of
specialist ophthalmologists, radiation oncologists and ocular on-
cology nurses, with the addition of medical oncologists, radiologists
and liver surgeons for systemic disease.
• Diagnostics must include ophthalmoscopy, ﬂuorescent and in-
docyanine angiography, OCT, fundus photography and ultra-
sonography (B-scan and UBM). In case of unclear diagnosis, a
transvitreal or transscleral ﬁne needle aspirate biopsy must be
considered. A full physical examination must be performed to ex-
clude systemic disease. Staging must be performed according to the
AJCC classiﬁcation (American Joint Committee on Cancer (AJCC),
2016; Angi et al., 2017).
• Ocular oncology centres must oﬀer radiotherapy (brachytherapy,
proton beam irradiation) and surgical treatments.
• All patients must have a 6 month check-up for liver metastasis by
ultrasound. Every patient treated with radiotherapy must have a
regular check-up in the ﬁrst 2 years for tumour control and re-
gression. After 2 years the check-up intervals depend on regression
of the tumour and complications of the radiotherapy.
• Genetic analysis for prognostication by analysis of chromosomal
aberrations (monosomy 3, extra copies of chromosome 8), expres-
sion arrays to determine class I or class I and/or BAP1 mutations
must only be performed after informed consent of the patient
(Dogrusözm and Jager, 2017).
• In metastatic disease, whole body staging must be performed, in-
cluding a physical examination, blood tests, and contrast-enhanced
CT-scan or PET-CT. Imaging of the brain is only indicated if there
are symptoms. Isolated liver perfusion and liver resection can be
considered if only liver metastases are present. There is no evidence
that checkpoint inhibitors are eﬀective in metastatic uveal mela-
noma.
3.4.10. Nursing
Nurses are the professionals who spend most time caring for people
with melanoma, and carry out a range of roles in the melanoma patient
care pathway. The need for melanoma nursing skills is corroborated by
England’s NICE in its recommendation for a specialised nursing role
(National Institute for Health and Care Excellence (NICE), 2015;
National Institute of Health and Care Excellence (NICE), 2016).
Essential requirements
• Nurses must have detailed insight into each patient’s experience on
the stages of their disease, proposed treatment and side-eﬀects
(Wheeler, 2009; Pullen et al., 2011).
• Nurses must conduct holistic assessments to ensure safe, persona-
lised and age-appropriate nursing care, and provide patient in-
formation and support that promotes self-eﬃcacy throughout the
patient journey. Validated instruments (e.g. distress thermometer)
must be used where appropriate and in conjunction with other MDT
members.
• Nursing interventions must be optimised to minimise side-eﬀects
(Thebeau et al., 2017) and to maximise treatment beneﬁt and
quality of life, in surgery (e.g. wound healing, lymphadenectomy),
radiotherapy (e.g. radiation-induced skin injury), chemotherapy
(e.g. neutropenia, sepsis), targeted therapies (e.g. adherence to the
regimen of oral small molecules, immunotherapy) (Duncan, 2015),
isolated limb perfusion, electroporation and clinical trials. Fatigue is
often mentioned by patients and must be considered by nurses.
• When performing advanced nursing roles (e.g. case manager, nurse
navigator, clinical nurse specialist), nurses must coordinate care
with healthcare professionals within and outside the core MDT, in-
cluding with nutrition, rehabilitation, psychosocial and palliative
care services.
3.5. Disciplines in the extended MDT
3.5.1. Geriatric oncology
The MDT must have access to geriatricians with oncology experi-
ence. The role of the geriatric oncologist is to coordinate re-
commendations to other specialists about the need for personalised
treatment for older patients with increased vulnerability to stressors.
Essential requirements
• Geriatric oncologists must ensure that older patients who are to
undergo extensive surgery or systemic treatment are screened for
frailty with a risk-assessment frailty screening tool (Hamaker et al.,
2012; Decoster et al., 2015; Huisman et al., 2014) and subsequent
comprehensive geriatric assessment when indicated. Whenever
possible an estimation of life expectancy (e.g. ePrognosis) may help
to prioritise medical interventions.
• A geriatric oncology team including geriatricians and other specia-
lists must be available for all vulnerable patients and their evalua-
tion must be discussed in the MDT meeting to oﬀer personalised
treatment.
• Geriatric oncologists must ensure the early integration of palliative
care plans or geriatric interventions, especially for vulnerable pa-
tients.
3.5.2. Oncology pharmacy
Oncology pharmacy plays a critical role in the care of melanoma
patients, given the growing importance of new treatments. The role of
the oncology pharmacist is to liaise with medical oncologists to discuss
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pharmaceutical treatment, supervise the preparation of oncology drugs,
work with nurses to manage therapy, counsel patients on their therapy,
and work in preventive programmes and palliative care.
Essential requirements
• Oncology pharmacists must work closely with medical oncologists
and nurses. They must have experience with interactions with other
drugs and foods and with dose adjustments based on age, liver and
kidney function, and knowledge of complementary and alternative
medicines. Oncology pharmacists must comply with the European
QuapoS guidelines (European Society of Oncology Pharmacy,
2014).
• Oncology pharmacists must work with medical oncologists and
nurses to minimise side-eﬀects and achieve best quality of life
concerning therapy, giving advice for example on skin care, wound
management, nutrition and management of adverse drug eﬀects.
• Oncology pharmacists must provide personalised information for
melanoma patients on their drug therapy to support adherence, i.e.
on the use of oral drugs.
• Oncology pharmacists must cooperate with medical oncologists on
clinical trials.
• Oncology drugs must be prepared in the pharmacy or designated
area that meets pharmacy criteria, and dispensing must take place
under the supervision of the oncology pharmacist.
3.5.3. Psycho-oncology
About 30% of melanoma patients report clinically signiﬁcant dis-
tress including anxiety and depression (Kasparian et al., 2009); symp-
toms of distress can continue into survivorship (Oliveria et al., 2013).
Common reactions include excessive worry and rumination, diﬃculty
concentrating, insomnia, increased use of alcohol and other drugs, so-
cial withdrawal and somatic complaints (Kasparian, 2013). There is
strong evidence that psychological intervention can improve psycho-
logical outcomes (Boesen et al., 2005; Dieng et al., 2016).
The role of the psycho-oncologist is to:
• Ensure that psychosocial distress (National Comprehensive Cancer
Network, 2003), and other psychological disorders and psychosocial
needs, are identiﬁed by screening throughout the disease con-
tinuum, and are considered by the MDT
• Promote eﬀective communication between patients, family mem-
bers and healthcare professionals
• Support patients and family members to cope with multifaceted
disease eﬀects
• Participate in prevention (i.e., identify emotional and behavioural
variables that interfere or facilitate preventive practices; increase
motivation to protect oneself from sun exposure, etc.).
Essential requirements
• Patients must have access to a self-administered psychological as-
sessment tool (‘distress thermometer’). Scores below a certain level
must be routinely managed by the primary care team; above that
level there must be further clinical interviewing and screening for
anxiety and depression, and referral to the most appropriate pro-
fessional, such as a mental health physician.
• Psychosocial care must be provided at all stages of the disease and
its treatment for patients and their families and must be present to
ensure comprehensive cancer care.
• In melanoma, psychological intervention must include motivation to
comply with treatment and prevention (sun protection); reduction
of psychological distress; addressing disﬁgurement; impact of dis-
tress on young adults and their life choices; survivorship issues such
as return to work; and dealing with treatment toxicities and lim-
itations.
• Psychosocial interventions must be based on clinical practice
guidelines or the NCCN Guidelines for Distress Management
(McLoone et al., 2013).
3.5.4. Paediatric oncology
Paediatric oncology literature suggests that the clinical history of
melanoma in children and adolescents resembles that of adult disease
(Ferrari et al., 2014). In the absence of speciﬁc guidelines on treatment
for children and adolescents, their management currently has the same
approach used for adults, though it is unclear whether melanoma de-
veloping at a very young age has the same biology (and the same tu-
mour driving mutations) of adult melanoma. There is a major challenge
in researching paediatric melanoma owing to its rarity.
Essential requirements
• Paediatric and adolescent melanoma patients must be treated in
close collaboration with a specialist adult melanoma centre.
• Paediatric doctors must be part of the MDT at all times for young
patients.
• The ERQCC expert group urges that all centres that treat paediatric
and adolescent melanoma participate in the European Cooperative
Study Group for Pediatric Rare Tumours (EXPeRT, http://www.
raretumors-children.eu) to work towards the goal of oﬀering new
drugs to paediatric melanoma patients (Ferrari et al., 2013).
3.5.5. Palliative care
Palliative care, as deﬁned by the World Health Organization
(http://www.who.int/cancer/palliative/deﬁnition), applies not only at
end of life but throughout cancer care. There is an increasing need for
palliative care throughout the disease trajectory, especially for patients
with locally advanced or metastatic melanoma to manage distressing
clinical complications and symptoms and to improve the quality of life
of patients and their families (Temel et al., 2010; Hui et al., 2015; Quill
and Abernethy, 2013).
The role of the palliative specialist is to:
• Manage specialist palliative care and make recommendations to
other specialists regarding general palliative care (e.g. symptom
control)
• Identify patients in need for palliative care through systematic as-
sessment of distressing physical, psychosocial and spiritual problems
• Provide early palliative care in conjunction with cancer speciﬁc
treatments, treat disease and treatment-related distressing symp-
toms such as pain and dyspnoea, and oﬀer psychosocial and spiritual
care
• Provide support for family members
• Provide end-of-life care and support decision making together with
primary care palliative care providers (Gallais Sörözal et al., 2016).
Essential requirements
• There must be a palliative care team that provides expert outpatient
and inpatient care.
• The palliative care team must include specialist physicians and
nurses, working with social workers, chaplains, physiotherapists,
occupational therapists, dieticians, pain specialists and the psycho-
oncology team.
• Palliative care specialists must have knowledge of cancer and side-
eﬀects of the oncological treatments (e.g. immune-related adverse
eﬀects), manage complications of complex skin tumours, and have
experience of taking care of young patients and their families.
• The palliative care unit must collaborate with community palliative
care teams.
• All patients with severe symptoms or suﬀering, or patients with
metastatic disease, irrespective of the cancer treatment plan, must
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also be in the care of the palliative care team.
3.5.6. Rehabilitation and survivorship
Elevated levels of distress and anxiety are experienced by melanoma
survivors, with fear of developing a subsequent melanoma present in
almost 75% (McLoone et al., 2011). Concerns regarding the impact of
the disease on children’s health is also frequently reported, given fa-
milial predisposition. Lack of consistent support and information
compounds stress and fears. Reassurance and optimal communication
with health professionals are considered an essential element of quality
care, and 64% of melanoma patients would like to receive more in-
formation from their health professionals during follow-up (Mitchell
et al., 2014). Families of patients should also be part of survivorship
plans.
Surveillance programmes currently vary among countries, and
guidelines are mainly based on the estimated risk of recurrence. Those
with early-stage melanoma may be referred to primary health care for
follow-up, the cornerstone of which is clinical examination (including
total body skin examination). High-risk patients usually remain within
specialised care, where signs of disease are being sought more actively
through more frequent visits and imaging studies. The patient’s con-
tribution to ﬁnding superﬁcial recurrences is important, as is reducing
risk from sun exposure.
Research is ongoing into the evidence base for cost-eﬀective sur-
veillance and the ERQCC expert group considers that health service
providers must keep abreast of the latest ﬁndings.
Essential requirements
• Many cancer patients are living longer after their treatment, and
must be well-informed about late-eﬀects, particularly relating to
surgery (lymphoedema and scarring) and immunotherapies (per-
manent endocrine and auto-immune issues), and recurrences and
how their lives could be aﬀected.
• Healthcare providers must adapt their guidelines on surveillance of
melanoma survivors for recurrences according to evidence for
(cost)-eﬀectiveness, which is likely to change as the impact of new
therapies becomes better known (Mrazek and Chao, 2014; Watts
et al., 2015; Rueth et al., 2015; Damude et al., 2016).
• Patients must be educated in self-monitoring of superﬁcial re-
currences.
• Rehabilitation and survivorship must be integrated into national
cancer plans and into policies concerning employment, welfare and
ﬁnancial services.
4. Other essential requirements
4.1. Patient involvement, access to information and transparency
• Patients must be involved in every step of the decision-making
process. Their satisfaction with their care must be assessed
throughout the patient care pathway. Patients must be oﬀered re-
levant and understandable information to help them appreciate the
process that will be followed with their treatment from the point of
diagnosis. They must be supported and encouraged to engage with
their health team to ask questions and obtain feedback on their
treatment wherever possible. Children need to be involved in an
age-appropriate manner and their parents/carers must be included
in the process as appropriate.
• It is also essential that melanoma patient support organisations are
involved whenever relevant throughout the patient pathway. These
groups work to:
○ Improve patients’ knowledge and ability to take decisions
○ Secure access to innovative therapies and improve quality of
treatment
○ Support melanoma research, such as by being involved in the
better design of clinical trials
○ Advocate at national health policy level.
• Euromelanoma (euromelanoma.org) is a pan-European campaign
and resource on skin cancer, prevention and early diagnosis.
Melanoma Patient Network Europe is a pan-European advocacy
network (melanomapatientnetworkeu.org), which also has links to
national melanoma patient groups in 17 European countries. The
European Skin Cancer Foundation is another pan-European body
(http://www.escf-network.eu). OcuMelUK (https://www.
ocumeluk.org) is a UK eye cancer charity. Organisations in the
USA working at global level include the Melanoma International
Foundation (melanomainternational.org), AIM at Melanoma (ai-
matmelanoma.org), and the Melanoma Research Foundation
(melanoma.org).
• Conclusions on each case discussion must be made available to pa-
tients and their primary care physician. Advice on seeking second
opinions must be supported.
• Cancer healthcare providers must publish on a website, or make
available to patients on request, data on centre/unit performance,
including:
○ Information services
○ Waiting times to ﬁrst appointment
○ Pathways of cancer care
○ Numbers of patients and treatments available at the centre
○ Number of operated patients at the centre (per procedure)
○ Clinical outcomes
○ Patient experience measurements (PREMs)
○ Incidents/adverse events
○ Clinical trials.
4.2. Performance and quality
The ERQCC expert group recommends that melanoma centres de-
velop:
• Performance measurement metrics/quality indicators based on the
essential requirements in this paper
• Operational policies to ensure the full beneﬁts of a coordinated
clinical pathway based on published guidelines
• Accountability within the governance processes in individual in-
stitutions
• Systems to ensure safe and high-quality patient care and experience
throughout the clinical pathway
• Eﬀective data management and reporting systems
• Engagement with patients, their carers and support groups to ensure
reporting of patient outcomes and experience.
To assess properly the quality of melanoma care, three categories of
outcomes must be measured and collected in databases at the level of
the specialist melanoma centre, regionally and/or nationally:
• Clinical outcomes
• Process outcomes
• Patient-reported outcomes (PROs).
This includes national audits where available and national cancer
registration/certiﬁcation.
These approaches can be developed in the context of quality man-
agement systems (QMS) depending on the health economy of an in-
dividual country. The beneﬁts of such a system include:
• Improving processes to enhance patient safety
• Setting standards within a clinical pathway
• Ensuring appropriate resource management including workforce
and ﬁnancial resources
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• Facilitating training opportunities
• Determining optimal outcomes with appropriate audit.
4.2.1. Audit of outcomes
Data measured and collected varies among countries but it is re-
commended that these outcome metrics are systematically measured
and collected for audit:
• % of patients discussed in the MDT prior to treatment
• % of patients discussed in the MDT after (surgical) treatment
• Proportion of patients according to clinical stage at time of diagnosis
• Proportion of patients receiving treatment with curative and pal-
liative intent
• Volume of speciﬁc curative procedures, such as the number of pa-
tients treated with ilio-inguinal lymph node dissection, ILP, targeted
therapies and immunotherapy
• Complications and toxicities
• In-hospital mortality
• 1 and 5-year overall survival rate
• Adherence to MDT recommendations.
4.2.2. Multidisciplinary team performance
• All MDT decisions must be documented in an understandable
manner, and must become part of patient records. Decisions taken
during MDT meetings must be monitored, and deviations reported
back to the MDT. It is essential that all relevant patient data, such as
pathology reports, meet quality standards and are available at the
time of the MDT meeting.
• The core and extended MDTs must meet at least twice a year to
review the activity of the previous period based on the audited
metrics, discuss changes in protocols and procedures, and improve
the performance of the unit/centre. MDT performance must be
quality assured both internally and by external review with de-
monstration of cost-eﬀectives of quality improvements, and MDT
guidance must be promoted nationally and written into national
cancer plans.
• The ERQCC expert group strongly recommends that further atten-
tion must be given to measures of PROs, not only to agree which
tools should be used, but also to use PROs more systematically as
part of discussions and evaluation within the MDT.
4.2.3. Accreditation
The ERQCC expert group strongly recommends participation in
national or international accreditation programmes, e.g. Organisation
of European Cancer Institutes (OECI) accreditation, http://oeci.
selfassessment.nu/cms (Wind et al., 2016).
4.2.4. National quality examples
Most national initiatives on quality in melanoma care are recent,
demonstrating that much work needs to be carried out to embed best
practice, and that variation in processes is likely to be uncovered. They
include the following.
• The National Institute of Health and Care Excellence (NICE) in
England and Wales published a quality standard for skin cancer in
2016.80 It has 7 statements that include referral for suspected mel-
anoma within 2 weeks, lesions examined with dermoscopy, access to
a skin cancer clinical nurse specialist for those with melanoma,
discussion about having a SLNB for those with a IB-IIC and> 1mm
thickness tumour, and those with metastatic or unresectable disease
should be oﬀered genetic testing.
• The National Health Service in Scotland published its ﬁrst mela-
noma quality performance indicators in 2016 (NHS Scotland, 2016).
The report details targets and performance against them. There are
11 indicators, including:
○ Patients with cutaneous melanoma having their diagnostic exci-
sion biopsy carried out by a skin cancer clinician
○ Surgical pathology reports for melanomas undergoing diagnostic
excision biopsy that contain a full set of data items
○ Patients with cutaneous melanoma discussed by a multi-
disciplinary team prior to deﬁnitive treatment.
○ Patients with primary cutaneous melanoma undergoing clinical
examination of their draining lymph node basins
○ BRAF status performed in all patients with unresectable stage III
or IV disease.
On the basis that there is considerable variation in the quality of
cancer care in the USA, a group identiﬁed melanoma care quality in-
dicators that hospitals can use to assess their adherence to melanoma
care guidelines (Bilimoria et al., 2009). The study rejected some quality
measures as impractical (such as surgical volumes owing to remote
areas) but, of valid measures, notably found low adherence to in-
dicators for lymph node evaluation.
In 2013, the ﬁrst German guidelines on the diagnosis, treatment and
follow-up of melanoma were published in the framework of the German
guideline programme on oncology, and 12 quality indicators were de-
veloped at the same time to implement the guideline recommendations
(Follmann et al., 2014). The indicators cover factors such as the mar-
gins of safety in excisions, lymph node ultrasound, SNLB, therapeutic
lymphadenectomy, post-op radiation, adjuvant and BRAF therapy, and
metastatic patients discussed by an MDT. Further, these indicators are
now being used in Germany’s cancer centre certiﬁcation programme.
A general paper on standardization and evolution of quality in-
dicators for melanoma surgery was published in 2017 (Pasquali et al.,
2017), and includes quality assurance examples from the Melanoma
Institute Australia, the Italian Melanoma Intergroup and the American
College of Surgeons. The paper has extensive references on the devel-
opment of surgical quality for melanoma.
The Dutch Melanoma Treatment Registry (DMTR) was set up in
2013 to improve the care of patients with advanced melanoma. It aims
to help carry out clinical auditing, improve transparency concerning the
quality of melanoma care, provide insight into real-world outcomes on
eﬀects and costs, and create a platform for research (Jochems et al.,
2017).
5. Education and training
It is essential that each melanoma centre provides professional
clinical and scientiﬁc education on the disease and that at least one
person is responsible for this programme. Healthcare professionals
working in melanoma must also receive training in psychosocial on-
cology, palliative care, rehabilitation and communication skills, tai-
lored to patient age where relevant. Such training must also be in-
corporated into specialist postgraduate and undergraduate curriculums
for physicians, nurses and other professionals. Nurses working in mel-
anoma centres should undertake post-qualiﬁcation education and
training about providing holistic care for people being treated for
melanoma throughout the patient journey.
6. Clinical research and population registries
• Centres treating melanomas must have clinical research pro-
grammes (either their own research or as a participant in pro-
grammes led by other centres). The research portfolio should have
both interventional and non-interventional projects and include
academic research. The MDT must assess all new patients for stages
II–IV for eligibility to take part in academic and industry sponsored
clinical trials at the centre or in research networks.
• Collaboration with European academic networks is strongly re-
commended − see the melanoma group of the European
Organisation for Research and Treatment of Cancer (EORTC –
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http://www.eortc.org) and the European Clinical Research
Infrastructure Network (ECRIN – http://www.ecrin.org). In coun-
tries where clinical trials are less available, centres treating mela-
noma should engage with policymakers to investigate referring pa-
tients to other countries (as proposed with European Reference
Networks) and should be prepared to participate in clinical trials
from an organisational standpoint. Researchers at other centres
should be considered as part of the extended MDT for at least annual
discussion of clinical trial participation. Generally, pan-European
action should be taken to increase participation of melanoma pa-
tients in clinical trials (both industry-sponsored and academic), and
internet access to local clinical trial databases should be developed.
• In paediatric oncology, participation in therapy optimising studies is
a standard of care in most countries. Children, adolescents, and
young adults in all countries should have access to national or in-
ternational multicentre studies, and accelerated access to innovative
therapies if their disease progresses (Gaspar and Fern, 2016).
• Older adults are currently underrepresented in cancer clinical trials
despite having a disproportionate burden of disease. Strategies to
increase the participation of older adults, adolescents and young
adults in clinical trials must be implemented and trials designed to
take their needs into account.
• Correlative biomarker research is a crucial part of all phases of
clinical studies, and requires close cooperation with biobanks such
as EORTC’s SPECTA programme (http://www.eortc.org/other-
research-initiatives/specta).
• National cancer control plans must include high-quality cancer re-
gistries for melanoma to inform both clinical research and to im-
prove the quality of care. An example is Nordcan (http://www-dep.
iarc.fr/NORDCAN), which includes melanoma in 50 cancer types in
the Nordic countries.
7. Conclusion
Taken together, the information presented in this paper provides a
comprehensive description of the essential requirements for estab-
lishing a high-quality melanoma service. The ERQCC expert group is
aware that it is not possible to propose a ‘one size ﬁts all’ system for all
countries, but urges that access to multidisciplinary teams and specia-
lised treatments is guaranteed to all patients with melanoma.
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